Catalent Completes Expansion of Clinical Supply Facility in Shanghai, China
SOMERSET, N.J. – December 1, 2022 — Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it has completed the expansion of its clinical supply facility in the Waigaoqiao Free Trade Zone (FTZ) in Shanghai, China.
The project has seen the site increase by approximately 30,000 square feet (approximately 2,800 square meters), which has allowed the installation of additional refrigerated (between 2 and 8 degrees Celsius) and deep-frozen (between minus 70 and minus 90 degrees Celsius) storage, and secondary packaging capabilities to be expanded. The completion will be marked by two customer events, on Dec. 1 and Dec. 6, where members of Catalent’s senior management team will be showcasing the facilities at the site and hosting workshops on clinical supply management and new GMP policies.
“China is the fastest growing clinical trials market in the Asia-Pacific region, and Catalent continues to invest and expand its facilities and services to offer reliable, flexible, and integrated support to customers,” said Tracey Clare, General Manager, APAC Operations, Catalent. “These additional capabilities increase the site’s ability to support clinical trials for advanced therapeutics, which often require specialized storage and handling capabilities.”
The Waigaoqiao facility is one of two clinical supply facilities that Catalent operates in Shanghai, the other being in Tangzhen, outside the FTZ. Together, they provide sponsors with optimized supply solutions for studies being undertaken in China, and through Catalent’s extensive network, the Asia-Pacific region and globally. These include clinical supply management, comparator sourcing, FastChain® demand-led supply, primary and secondary packaging, storage, and global distribution, as well as clinical returns and destruction.
NOTES FOR EDITORS
Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.
Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians.
Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit www.catalent.com.